Pokroky ve využití organokovových sloučenin při vývoji protinádorových léčiv


This publication doesn't include Faculty of Medicine. It includes Faculty of Science. Official publication website can be found on muni.cz.
Title in English Progress in the Utilisation of Organometallic Compounds in the Development of Cancer Drugs


Year of publication 2019
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Science

Web https://www.linkos.cz/casopis-klinicka-onkologie/2019-10-14-supplementum-3/pokroky-ve-vyuziti-organokovovych-sloucenin-pri-vyvoji-protinadorovych-leciv/
Doi http://dx.doi.org/10.14735/amko20193S.
Keywords cancer-chemotherapy-drugs-organometallic compounds-titanium-ruthenium
Description Background: Organometallic compounds are chemical substances containing a carbon-metal bond. From a biological point of view, these compounds are generally considered to be toxic for living organisms. They may exert therapeutic potential, especially as anticancer or antimicrobial drugs. Particularly advantageous properties are structural variability and usually uncharged and mostly lipophilic character. Platinum derivatives are the most proven agents in the medical field, predominately cisplatin. The success of cisplatin leads the scientific community to focus on the synthesis of other organometallic compounds with improved anti-tumor effects and lower cytotoxicity towards healthy tissues. Great attention is focused on compounds bearing atoms of iron, titanium or ruthenium. Purpose: Here we focus on summarizing description of the most important compounds containing Fe, Ti, or Ru atoms in their structure, showing potential application in cancer treatment including the mechanism of action for some of the most studied compounds. Reported structures were successfully used in preclinical studies including animal models and progressed to various stages of human clinical trials. Despite the failures of some of these compounds, there are still several candidates who are expected to progress to the late stages of the clinical trials either alone or as part of a combined chemotherapy. Especially, ruthenium-containing substances show high potential for utilization in cancer treatment due to low cytotoxicity associated with the ability to block neoangiogenesis and metastasis development.

You are running an old browser version. We recommend updating your browser to its latest version.

More info